|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 February 2002, Vol. 99, No. 3, pp. 1014-1022
NEOPLASIA
Synergic effects of arsenic trioxide and cAMP during acute
promyelocytic leukemia cell maturation subtends a novel signaling
cross-talk
Qi Zhu,
Ji-Wang Zhang,
Hai-Qing Zhu,
Yu-Lei Shen,
Maria Flexor,
Pei-Ming Jia,
Yun Yu,
Xun Cai,
Samuel Waxman,
Michel Lanotte,
Sai-Juan Chen,
Zhu Chen, and
Jian-Hua Tong
From the Shanghai Institute of Hematology and Key
Laboratory for Human Genome Research, Rui Jin Hospital, Shanghai Second
Medical University, Shanghai, China; INSERM U496, Centre G. Hayem,
Hopital Saint Louis, Paris, France; and Division of Neoplastic
Diseases, Department of Medicine, The Mount Sinai Medical Center, New
York, NY.
Acute promyelocytic leukemia (APL) is characterized by the specific
chromosome translocation t(15;17) with promyelocytic leukemia-retinoic acid receptor- (PML-RARA) fusion gene and the
ability to undergo terminal differentiation as an effect of
all-trans retinoic acid (ATRA). Recently, arsenic trioxide
(As2O3) has been identified as an alternative
therapy in patients with both ATRA-sensitive and ATRA-resistant APL. At
the cellular level, As2O3 triggers apoptosis
and a partial differentiation of APL cells in a dose-dependent manner;
both effects are observed in vivo among patients with APL and APL
animal models. To further explore the mechanism of As2O3-induced differentiation, the combined
effects of arsenic and a number of other differentiation
inducers on APL cell lines (NB4 and NB4-R1) and some fresh APL cells
were examined. The data show that a strong synergy exists between a low
concentration of As2O3 (0.25 µM) and the
cyclic adenosine monophosphate (cAMP) analogue, 8-CPT-cAMP, in fully
inducing differentiation of NB4, NB4-R1, and fresh APL cells.
Furthermore, cAMP facilitated the degradation of
As2O3-mediated fusion protein PML-RAR , a
process considered to play a key role in overcoming the differentiation arrest of APL cells. On the other hand, cAMP could significantly inhibit cell growth by modulating several major players in
G1/S transition regulation. Interestingly, H89, an
antagonist of protein kinase A, could block the
differentiation-inducing effect of As2O3 potentiated by cAMP. These results thus support the existence of a
novel signaling cross-talk for APL maturation, which may deepen
understanding of As2O3-induced differentiation
in vivo, and thus furnish insights for new therapeutic strategies.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Z.-Y. Wang and Z. Chen
Acute promyelocytic leukemia: from highly fatal to highly curable
Blood,
March 1, 2008;
111(5):
2505 - 2515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Catalano, M. A. Dawson, K. Somana, S. Opat, A. Schwarer, L. J. Campbell, and H. Iland
The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia
Blood,
December 1, 2007;
110(12):
4073 - 4076.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Shackelford, C. Kenific, A. Blusztajn, S. Waxman, and R. Ren
Targeted Degradation of the AML1/MDS1/EVI1 Oncoprotein by Arsenic Trioxide
Cancer Res.,
December 1, 2006;
66(23):
11360 - 11369.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D.-R. Hwang, Y.-C. Tsai, J.-C. Lee, K.-K. Huang, R.-K. Lin, C.-H. Ho, J.-M. Chiou, Y.-T. Lin, J. T. A. Hsu, and C.-T. Yeh
Inhibition of Hepatitis C Virus Replication by Arsenic Trioxide
Antimicrob. Agents Chemother.,
August 1, 2004;
48(8):
2876 - 2882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Kamashev, D. Vitoux, and H. de The
PML-RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation
J. Exp. Med.,
April 19, 2004;
199(8):
1163 - 1174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-X. Shen, Z.-Z. Shi, J. Fang, B.-W. Gu, J.-M. Li, Y.-M. Zhu, J.-Y. Shi, P.-Z. Zheng, H. Yan, Y.-F. Liu, et al.
Inaugural Article: All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia
PNAS,
April 13, 2004;
101(15):
5328 - 5335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-y. Wang
Ham-Wasserman Lecture: Treatment of Acute Leukemia by Inducing Differentiation and Apoptosis
Hematology,
January 1, 2003;
2003(1):
1 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-C. Guillemin, E. Raffoux, D. Vitoux, S. Kogan, H. Soilihi, V. Lallemand-Breitenbach, J. Zhu, A. Janin, M.-T. Daniel, B. Gourmel, et al.
In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic Leukemia
J. Exp. Med.,
November 18, 2002;
196(10):
1373 - 1380.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |